Covalon Launches Centaur Low Particulate, Lubricious Coating for Medical Devices

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

April 27, 2017

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV), an advanced medical technologies company, today announced the launch of its new, Centaur™ low particulate, lubricious coating designed to improve the safety and functionality of intravascular medical devices such as catheters, guidewires and delivery sheaths where the presence of unwanted particulate can cause significant patient complications.

Covalon notes in a third party in vitro simulated vascular insertion study designed to measure the levels of particulate, Covalon’s Centaur ™ coating resulted in statistically significantly lower levels for all particulate sizes relative to the same uncoated catheter. This contrasts with other industry-leading coatings that can generate nearly twice as many particles as the same uncoated catheter. Covalon’s Centaur™ coating technology specifically targets and is ideally suited for a growing segment of the medical coatings market focused on improving lubricity while maintaining coating durability.

“We are very excited about these results,” said Val DiTizio, Covalon’s Chief Scientific Officer. “Being able to show that a coated catheter can have fewer particles than even an uncoated catheter positions our patented technology ahead of the current leading medical coating processes.”

In November of 2015, the U.S. Food and Drug Administration (FDA) issued a safety communication regarding lubricious coatings separating from vascular access devices. It states that since January 1, 2010, there have been 11 recalls from various manufacturers associated with these coatings peeling or flaking off of medical devices. The majority of the recalls were associated with guidewires, but there have also been recalled for other types of devices including sheaths, retrieval devices, and embolization device delivery wires used in the vasculature.1

“The combination of recent recalls and a market for medical device coatings that is expected to grow to $15 billion by 2025, makes our launch of a highly differentiated medical coating like Centaur that has a potentially more favourable safety profile than its competitors an exciting opportunity for our coatings business,” said John R. Hands, Executive Vice President at Covalon. “Our new Centaur low particulate, lubricious coating can help medical device manufacturers introduce new lines of coated catheters, guidewires and stents that provide a higher level of confidence to clinicians when using their medical devices.”

Covalon collaborates with industry leading medical device companies to develop custom medical device coatings that offer a unique, strategic advantage for their product offerings. The proprietary CovaCoat™ and Centaur™ technologies provide a cost-effective coating process for exceptional functionality and performance for a variety of medical device surfaces.



Related Articles